Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3746]

ASH 2025: Home-based monitoring could transform care for patients receiving T-cell redirecting therapies

ASH 2025: Home-based monitoring could transform care for patients receiving T-cell redirecting therapies

ASH 2025: Developed antibody boosts immune response against blood cancers and solid cancers

ASH 2025: Developed antibody boosts immune response against blood cancers and solid cancers

$ASH 2025: Tec-Dara combination offers substantial improvement over standard second-line therapies for relapsed or refractory multiple myeloma$

ASH 2025: Tec-Dara combination offers substantial improvement over standard second-line therapies for relapsed or...

ASH 2025: Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL

ASH 2025: Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL

Lower doses of immunotherapy for skin cancer give better results

Lower doses of immunotherapy for skin cancer give better results

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial

ASH 2025: CAR T cell therapy shows promising phase II trial results in multiple myeloma

ASH 2025: CAR T cell therapy shows promising phase II trial results in multiple myeloma

New organ-on-a-chip platform allows the testing of cancer vaccine efficacy in ageing populations

New organ-on-a-chip platform allows the testing of cancer vaccine efficacy in ageing populations

Pathway discovered to make the most common breast cancer tumour responsive to immunotherapy

Pathway discovered to make the most common breast cancer tumour responsive to immunotherapy

Antibody halts triple-negative breast cancer in preclinical models

Antibody halts triple-negative breast cancer in preclinical models

More from ecancer